Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials
Authors:
- Calvin J. CohenCCCalvin J. Cohen
- Jean-Michel MolinaJMJean-Michel Molina
- Isabel CassettiICIsabel Cassetti
- Ploenchan ChetchotisakdPCPloenchan Chetchotisakd
- Adriano LazzarinALAdriano Lazzarin
- Chloe OrkinCOChloe Orkin
- Frank RhameFRFrank Rhame
- Hans-Jürgen StellbrinkHSHans-Jürgen Stellbrink
- Taisheng LiTLTaisheng Li
- Herta CrauwelsHCHerta Crauwels
- Laurence RimskyLRLaurence Rimsky
- Simon VanveggelSVSimon Vanveggel
- 27 March 2013
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 27 (6) , 939-950
Abstract
In the week 48 primary analysis of ECHO and THRIVE, rilpivirine demonstrated noninferior efficacy and more favourable tolerability versus efavirenz in treatment-naive, HIV-1-infected adults. Pooled 96-week results are presented. Patients (N = 1368) received rilpivirine 25 mg once-daily (q.d.) or efavirenz 600 mg q.d., with two background nucleoside/nucleotide reverse transcriptase inhibitors, in two randomized, double-blind, double-dummy Phase III trials. At week 96, response rate (% confirmed viral load <50 copies/ml; intent-to-treat, time-to-loss-of-virologic response) was 78% in both groups. Responses were similar for both treatments by background regimen, sex, race, and in patients with more than 95% adherence (M-MASRI) or baseline viral load 100,000 copies/ml or less. Responses were lower and virologic failure higher for rilpivirine versus efavirenz in patients with 95% or less adherence or baseline viral load more than 100,000 copies/ml. Beyond week 48, the incidence of virologic failure was comparable (3 versus 2%) between treatment groups, rilpivirine resistance-associated mutations were consistent with those observed in year 1, there were few adverse events in both groups and no new safety concerns. Over 96 weeks, discontinuations due to adverse events (4 versus 9%), treatment-related grade 2-4 adverse events (17 versus 33%), rash (4 versus 15%), dizziness (8 versus 27%) and abnormal dreams/nightmares (8 versus 13%), and grade 2-4 lipid abnormalities were lower with rilpivirine than efavirenz. Only 2 and 4% of patients in the rilpivirine and efavirenz treatment groups, respectively, reported at least possibly treatment-related grade 2-4 adverse events during the second year of treatment. Rilpivirine 25 mg q.d. and efavirenz 600 mg q.d. had comparable responses at week 96. Rilpivirine had more virologic failures but improved tolerability versus efavirenz. The majority of virologic failures occurred in the first 48 weeks.Keywords
This publication has 23 references indexed in Scilit:
- Antiretroviral Treatment of Adult HIV InfectionJAMA, 2012
- Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialThe Lancet, 2011
- The frequency and reasons for antiretroviral switching with specific antiretroviral associations: The SWITCH studyAntiviral Research, 2010
- Effects of First-Line Use of Nucleoside Analogues, Efavirenz, and Ritonavir-Boosted Protease Inhibitors on Lipid LevelsHIV Research & Clinical Practice, 2009
- Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C CoinfectionAIDS Research and Human Retroviruses, 2005
- Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1PLOS Medicine, 2004
- Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyThe Lancet, 2004
- Patterns and Correlates of Discontinuation of the Initial HAART Regimen in an Urban Outpatient CohortJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Safety and Tolerance of Efavirenz in Different Antiretroviral Regimens: Results from a National Multicenter Prospective Study in 1,033 HIV-Infected PatientsHIV Research & Clinical Practice, 2002